消息
×
loading..
×
验证码:
换一张
忘记密码?
记住我
×
统一认证登录
登录
中文版
|
English
上海科技大学知识管理系统
ShanghaiTech University Knowledge Management System
统一认证登录
登录
注册
ALL
ORCID
题名
作者
发表日期
关键词
文献类型
DOI
出处
存缴日期
收录类别
出版者
学习讨论厅
图片搜索
粘贴图片网址
首页
研究单元&专题
作者
文献类型
学科分类
知识图谱
知识整合
学习讨论厅
反馈留言
个人主页
个人信息
个人简介
科研成果
期刊论文(10)
专利(5)
来源
EUROPEAN JOURNAL OF MEDICI...(2)
EXPERIMENTAL HEMATOLOGY & ...(2)
ACTA PHARMACOLOGICA SINICA(1)
ACTA PHARMACOLOGICA SINICA...(1)
ADVANCED SCIENCE(1)
CANCER MEDICINE(1)
收录类别
SCI(8)
EI(1)
SCOPUS(1)
访问统计
来源
EUROPEAN JOURNAL OF MEDICI...(2)
EXPERIMENTAL HEMATOLOGY & ...(2)
ACTA PHARMACOLOGICA SINICA(1)
ACTA PHARMACOLOGICA SINICA...(1)
ADVANCED SCIENCE(1)
CANCER MEDICINE(1)
CANCER RESEARCH(1)
JOURNAL OF MEDICINAL CHEMI...(1)
发表日期
2025(4)
2024(4)
2023(7)
关键词云
More»
成果统计
More»
×
知识图谱
合作作者[TOP 5]
点击查看合作网络
蒋华良
合作成果数:9
王亚芳
合作成果数:8
程建军
合作成果数:5
闫文仲
合作成果数:4
Shen, Jie
合作成果数:4
合作作者
蒋华良
合作成果数:9
王亚芳
合作成果数:8
程建军
合作成果数:5
闫文仲
合作成果数:4
Shen, Jie
合作成果数:4
Yu, Chengcheng
合作成果数:4
Yao, Mingyue
合作成果数:3
姜标
合作成果数:2
王林
合作成果数:2
白芳
合作成果数:2
张向磊
合作成果数:2
吴洒男
合作成果数:2
赵昱
合作成果数:2
杨可馨
合作成果数:2
李成
合作成果数:2
陈雨君
合作成果数:2
石尚轩
合作成果数:2
Li, Yingnian
合作成果数:2
Mingyue Yao
合作成果数:2
访问统计
总访问量
600
访问来源
内部: 0
外部: 600
国内: 549
国外: 51
年访问量
160
访问来源
内部: 0
外部: 160
国内: 150
国外: 10
月访问量
3
访问来源
内部: 0
外部: 3
国内: 3
国外: 0
访问量
访问量
1.
Discovery, structural optimization, and anti-tumor bioactivity eva..
[573]
2.
五环三萜衍生物的医药用途、五环三萜衍生物、包含其的药物组合物
[537]
3.
三唑酰胺类化合物及其制备方法和用途
[466]
4.
Design and Synthesis of Triazole-Containing HDAC Inhibitors That I..
[437]
5.
Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance th..
[399]
6.
Discovery of Novel BCL6-Targeting PROTACs with Effective Antitumor..
[389]
7.
嘧啶并环类化合物、其制备方法和应用
[384]
8.
Unraveling the CDK9/PP2A/ERK Network in Transcriptional Pause Rele..
[377]
9.
三唑酰胺类化合物及其制备方法和用途
[372]
10.
SOS1蛋白降解剂及其应用
[370]
11.
143D, a novel selective KRASG12C inhibitor exhibits potent antitum..
[348]
12.
Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity a..
[202]
13.
Mutation in CDC42 Gene Set as a Response Biomarker for Immune Chec..
[139]
14.
Concurrent inhibition of p300/CBP and FLT3 enhances cytotoxicity a..
[111]
15.
IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inh..
[104]
下载量
1.
Discovery of Novel BCL6-Targeting PROTACs with Effective Antitumor..
[13]
2.
Discovery, structural optimization, and anti-tumor bioactivity eva..
[8]
3.
Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity a..
[8]
4.
Concurrent inhibition of p300/CBP and FLT3 enhances cytotoxicity a..
[8]
5.
Design and Synthesis of Triazole-Containing HDAC Inhibitors That I..
[7]
6.
Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance th..
[5]
7.
IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inh..
[5]
8.
143D, a novel selective KRASG12C inhibitor exhibits potent antitum..
[4]
9.
Unraveling the CDK9/PP2A/ERK Network in Transcriptional Pause Rele..
[3]
10.
五环三萜衍生物的医药用途、五环三萜衍生物、包含其的药物组合物
[1]
11.
Mutation in CDC42 Gene Set as a Response Biomarker for Immune Chec..
[1]
科研成果
15
5208
63
37
0
3
Items
Views
Downloads
TC[WOS]
TC[CSCD]
H-index
排序方式:
按发表日期降序
按发表日期升序
按WOS被引频次降序
按期刊影响因子降序
正在努力地加载数据中,请稍候……
[1]
Yao, Mingyue.,Yan, Wenzhong.,Wang, Yafang.,Zhao, Yu.,Xu, Xiaowei.,...&Xie, Chengying.(2025).IHCH9033, a novel class I HDAC inhibitor, synergizes with FLT3 inhibitor and rescues quizartinib resistance in FLT3-ITD AML via enhancing DNA damage response.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
,14(1).
浏览/下载:
104/5
; 被引[WOS]:
1
; IF:
9.4
/
8.3
评论
推荐
收藏
[2]
Luo, Ziwei.,Lin, Chencen.,Yu, Chuwei.,Yuan, Changxian.,Wu, Wenyong.,...&Xie, Chengying.(2025).Targeted Degradation of SOS1 Exhibits Potent Anticancer Activity and Overcomes Resistance in KRAS-Mutant Tumors and BCR-ABL-Positive Leukemia.
CANCER RESEARCH
,85(1).
浏览/下载:
202/8
; 被引[WOS]:
0
; IF:
12.5
/
11.6
评论
推荐
收藏
[3]
Wang, Kun.,Zhang, Yingying.,Su, Zhaoming.,Wang, Bei.,Zhou, Yuanyang.,...&Zheng, Mingyue.(2025).Mutation in CDC42 Gene Set as a Response Biomarker for Immune Checkpoint Inhibitor Therapy.
CANCER MEDICINE
,14(1).
浏览/下载:
139/1
; 被引[WOS]:
0
; IF:
2.9
/
3.9
评论
推荐
收藏
[4]
Chen, Yu-jun.,Zhao, Yu.,Yao, Ming-yue.,Wang, Ya-fang.,Ma, Ming.,...&Xie, Cheng-ying.(2025).Concurrent inhibition of p300/CBP and FLT3 enhances cytotoxicity and overcomes resistance in acute myeloid leukemia.
ACTA PHARMACOLOGICA SINICA
.
浏览/下载:
111/8
; 被引[WOS]:
1
; IF:
6.9
/
7.6
评论
推荐
收藏
[5]
谢成英,姜标,杨小宝. Sos1蛋白降解剂及其应用. 2024-10-22.
浏览/下载:
370/0
评论
推荐
收藏
[6]
Dazhao Mi.,Cheng Li.,Yuzhan Li.,Mingyue Yao.,Yan Li.,...&Yihua Cheng.(2024).Discovery of Novel BCL6-Targeting PROTACs with Effective Antitumor Activities against DLBCL in Vitro and in Vivo.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
,277.
浏览/下载:
389/13
; 被引[WOS]:
4
; IF:
6.0
/
6.1
评论
推荐
收藏
[7]
梅良和,谢成英,白芳,等. 五环三萜衍生物的医药用途、五环三萜衍生物、包含其的药物组合物. 2024-03-22.
浏览/下载:
537/1
评论
推荐
收藏
[8]
Wang, Yafang.,Xu, Lansong.,Ling, Lijun.,Yao, Mingyue.,Shi, Shangxuan.,...&Xie, Chengying.(2024).Unraveling the CDK9/PP2A/ERK Network in Transcriptional Pause Release and Complement Activation in KRAS-mutant Cancers.
ADVANCED SCIENCE
,11(41).
浏览/下载:
377/3
; 被引[WOS]:
0
; IF:
14.3
/
16.3
评论
推荐
收藏
[9]
Yafang Wang.,Mingyue Yao.,Cheng Li .,Kexin Yang.,Xiaolong Qin.,...&Chengying Xie.(2023).Targeting ST8SIA6-AS1 counteracts KRASG12C inhibitor resistance through abolishing the reciprocal activation of PLK1/c-Myc signaling.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY
.
浏览/下载:
399/5
; 被引[WOS]:
13
; IF:
9.4
/
8.3
评论
推荐
收藏
[10]
Cheng Jianjun,Xie Chengying,Yan Wenzhong,等. 三唑酰胺类化合物及其制备方法和用途. 2023-10-05.
浏览/下载:
372/0
评论
推荐
收藏
每页显示
10
0
条
‹
1
2
›